Mexico

COFEPRIS, operating under the Secretaria de Salud (SSa), is the primary regulatory authority responsible for evaluating and authorizing health products in Mexico, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. The main governing legislation includes the Ley General de Salud (General Health Law), the Reglamento de Insumos para la Salud, and a series of Normas Oficiales Mexicanas (NOMs) that establish technical and safety standards for specific product categories. The authorization process generally involves submission of a marketing authorization dossier, technical review by COFEPRIS committees, and, for pharmaceuticals, potential bioequivalence or clinical data requirements. Medical devices are classified into three risk classes (Class I, II, and III), with higher-risk products subject to more rigorous premarket review. In recent years, COFEPRIS has faced institutional changes, including its partial restructuring into the Agencia de Alimentos y Medicamentos (AgaMed) under ongoing health system reforms, introducing some uncertainty around timelines and procedural continuity.

A key requirement for foreign manufacturers is the appointment of a local legal representative or Responsable Sanitario, who assumes regulatory accountability within Mexico and serves as the primary point of contact with COFEPRIS. Dossiers are generally submitted in Spanish and are expected to follow formats aligned with the Common Technical Document (CTD) structure for pharmaceuticals, while medical device submissions reference applicable NOMs and may incorporate international standards such as ISO 13485. Mexico is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and has pursued convergence with regulatory frameworks from the United States FDA, European EMA, and other reference authorities, allowing for recognition of foreign approvals in certain accelerated pathways. Recent reforms have also emphasized the use of third-party conformity assessment bodies (Organismos de Certificacion) for medical device evaluation, and digital health products are increasingly subject to regulatory scrutiny, though a dedicated digital health regulatory framework remains under development.

Public procurement of health products in Mexico is managed through a multi-layered federal and state structure. At the federal level, the Instituto Mexicano del Seguro Social (IMSS), the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), and the Secretaria de Salud coordinate the largest procurement volumes, historically through centralized consolidated tenders managed by entities such as the Oficina de las Naciones Unidas de Servicios para Proyectos (UNOPS), which was engaged by the Mexican government to conduct international public tenders for medicines and medical supplies. The Ley de Adquisiciones, Arrendamientos y Servicios del Sector Publico (LAASSP) governs federal procurement procedures, mandating open tendering processes, price transparency, and registration on the CompraNet public procurement platform. State-level health ministries (Servicios Estatales de Salud, SESA) also conduct their own procurement for products not covered under federal consolidated purchases, creating a fragmented secondary market with varying timelines and requirements. Products must hold a valid COFEPRIS marketing authorization and be listed in applicable formularies, such as the Cuadro Basico y Catalogo de Insumos del Sector Salud, to be eligible for public procurement.

The private sector represents a significant and growing channel in Mexico, driven by a large out-of-pocket expenditure base and an expanding network of private hospitals, clinics, and pharmacy chains such as Farmacias Similares and Farmacias del Ahorro. Distribution in the private market typically occurs through authorized distributors and wholesalers who operate under COFEPRIS licensing requirements. Donor-funded procurement through international agencies such as UNICEF, PAHO, and the Global Fund plays a more limited role compared to lower-income markets in the region, though these channels have been utilized for specific disease programs including HIV, tuberculosis, and neglected tropical diseases. Mexico does not enforce formal local manufacturing preference mandates with the same rigor as some other markets, but government policy increasingly favors domestic industry development through initiatives supporting national pharmaceutical and biotechnology production capacity, and certain public tender criteria may award preference points to locally manufactured or nationally sourced products.